The European Commission and European Medicines Agency (EMA) have published a Q&A document (the EMA Q&A) concerning the legal consequences for marketing authorisation holders (MAHs) of centrally authorised medicines if the UK becomes a ‘third country’ after Brexit. The EMA Q&A provides further detail following the European Commission and EMA notice of 2 May 2017.
Latest Post
More Posts
FDA / EMA parallel scientific advice principles published
European Union’s new medical device regulations come into force
Recent European developments in mHealth regulation
NICE to fast-track more medicine approvals but wider changes do not impress industry
European and US regulators’ agreement on mutual recognition of inspections of medicines manufacturers
New NHS England conflict of interest guidelines
The UK Government’s Brexit White Paper and its impact on the life sciences sector
Biologics: what’s in a name? Health Canada and EMA take a different approach from FDA
The UK Government’s Brexit plan and its implications for life sciences
Subscribe: Subscribe via RSS
Firm/Org